RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS

Core Insights - MariTide, a novel obesity treatment, has shown significant efficacy with up to ~20% average weight loss in individuals without Type 2 diabetes and ~17% in those with Type 2 diabetes, without reaching a weight loss plateau at 52 weeks [1][3][4] - The treatment also resulted in substantial improvements in cardiometabolic health, including reductions in HbA1c levels and various cardiovascular risk factors [3][4][5] - The Phase 3 MARITIME studies are set to evaluate MariTide's safety and efficacy in broader populations, including those with atherosclerotic cardiovascular disease and heart failure, with initiation planned for 2025 [2][6] Company Overview - Amgen is advancing MariTide as a long-acting peptide-antibody conjugate administered monthly or less frequently, aiming to enhance patient adherence and long-term weight management [2][4][20] - The company has a robust pipeline addressing obesity, including both oral and injectable treatments, leveraging its expertise in genetic research to optimize therapeutic outcomes [21][22] Clinical Study Details - The Phase 2 study enrolled 592 adults, divided into two cohorts based on the presence of Type 2 diabetes, with significant weight loss observed across various dosing regimens [8][9] - The Phase 1 pharmacokinetics low dose initiation study demonstrated that lower starting doses improved gastrointestinal tolerability without compromising efficacy [4][5][15] Future Directions - The ongoing Phase 3 studies will further assess MariTide's impact on chronic weight management and its potential benefits for patients with obesity-related conditions [6][10] - Amgen plans to initiate additional Phase 3 studies targeting cardiovascular diseases and obstructive sleep apnea in 2025, expanding the therapeutic applications of MariTide [2][6]